---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-008077"
form_type: "8-K"
ticker: "PURE"
cik: "0001006028"
company_name: "PURE BIOSCIENCE, INC."
filed_at: "2023-03-17T23:59:59+00:00"
generated_at: "2026-06-17T23:25:36.863881+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PURE Bioscience Q2 net loss widens to $1.06M; CEO Tom Y. Lee resigns, Robert Bartlett appointed

## Summary
- Q2 net product sales $396K, down ~4.6% YoY; net loss $1.06M vs $702K prior year.
- Six-month net loss $2.05M vs $1.50M; loss per share ($0.02) unchanged.
- CEO Tom Y. Lee resigned March 15; Robert Bartlett named President and CEO.
- Tom Myers transitions from COO to EVP Technology & Development for sales and R&D focus.
- New CEO says prior sales approach lackluster; plans to refocus on new and existing channels.

## SEC filing metadata
- accession: 0001493152-23-008077
- form_type: 8-K
- ticker: PURE
- cik: 0001006028
- company_name: PURE BIOSCIENCE, INC.
- filed_at: 2023-03-17T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006028/000149315223008077/0001493152-23-008077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006028/000149315223008077/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-008077
- JSON: https://secwatch.observer/filing/0001493152-23-008077.json
- Plain text: https://secwatch.observer/filing/0001493152-23-008077.txt

## Key facts
- Earnings Releases
  PURE BIOSCIENCE, INC. reported fiscal second quarter ended January 31, 2023 results: revenue $396,000, net income $1,060,000, EPS ($0.01).
  - Period: fiscal second quarter ended January 31, 2023
  - Revenue: $396,000
  - Net income: $1,060,000
  - EPS: ($0.01)
  - Result: reported results
  source text: Q2: Summary of Results of Operations ● Net product sales were $396,000 and $415,000 for the fiscal second quarter ended January 31, 2023 and 2022, respectively. The decrease of $19,000 was attributable to decreased sales across our distribution network. ● Net loss for the fiscal second quarter ended January 31, 2023 was $1,060,000, compared to $702,000 for the fiscal second quarter ended January 31, 2022. ● Net loss, excluding share-based compensation, for the fiscal second quarter ended January 31, 2023 was $933,000, compared to $522,000 for the fiscal second quarter ended January 31, 2022. ● Net loss per share was ($0.01) for the fiscal second quarters ended January 31, 2023 and 2022, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006028/000149315223008077/0001493152-23-008077-index.htm
- Earnings Releases
  PURE BIOSCIENCE, INC. reported six months ended January 31, 2023 results: revenue $863,000, net income $2,053,000, EPS ($0.02).
  - Period: six months ended January 31, 2023
  - Revenue: $863,000
  - Net income: $2,053,000
  - EPS: ($0.02)
  - Result: reported results
  source text: Six Months: Summary of Results of Operations ● Net product sales were $863,000 and $912,000 for the six months ended January 31, 2023 and 2022, respectively. The decrease of $49,000 was attributable to decreased sales across our transportation and distribution network. ● Net loss for the six months ended January 31, 2023 was $2,053,000, compared to $1,498,000 for the six months ended January 31, 2022. ● Net loss, excluding share-based compensation, for the six months ended January 31, 2023 was $1,842,000, compared to $1,128,000 for the six months ended January 31, 2022. ● Net loss per share was ($0.02) for the six months ended January 31, 2023 and 2022, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006028/000149315223008077/0001493152-23-008077-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.